• Clarivate issued an amended Form 8-K/A detailing the completed sale of its Life Sciences and Healthcare business to an Altaris affiliate for USD 600 million.
• The transaction closed on Oct. 6, 2026, with Clarivate receiving USD 488.4 million in cash at close, net of closing costs and working-capital adjustments.
• The deal includes a USD 75 million unsecured senior note, with USD 25 million of deferred cash consideration due no later than Jan. 31, 2028.
• Clarivate said the divestiture represents a strategic shift and qualified for discontinued-operations accounting in the third quarter of 2026.
• It does not expect the gain or loss on sale to be material.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarivate plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001764046-26-000122), on October 13, 2026, and is solely responsible for the information contained therein.